PL2508182T3 - Hydralazyna do stosowania w leczeniu związanego z wiekiem zwyrodnienia plamki - Google Patents

Hydralazyna do stosowania w leczeniu związanego z wiekiem zwyrodnienia plamki

Info

Publication number
PL2508182T3
PL2508182T3 PL12173008T PL12173008T PL2508182T3 PL 2508182 T3 PL2508182 T3 PL 2508182T3 PL 12173008 T PL12173008 T PL 12173008T PL 12173008 T PL12173008 T PL 12173008T PL 2508182 T3 PL2508182 T3 PL 2508182T3
Authority
PL
Poland
Prior art keywords
hydralazine
age
treatment
macular degeneration
related macular
Prior art date
Application number
PL12173008T
Other languages
English (en)
Polish (pl)
Inventor
George C. Chiou
Original Assignee
The Texas A & M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Texas A & M University System filed Critical The Texas A & M University System
Publication of PL2508182T3 publication Critical patent/PL2508182T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12173008T 2005-05-12 2006-05-04 Hydralazyna do stosowania w leczeniu związanego z wiekiem zwyrodnienia plamki PL2508182T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68099805P 2005-05-12 2005-05-12
US77642606P 2006-02-24 2006-02-24
US11/416,773 US8088773B2 (en) 2005-05-12 2006-05-03 Therapeutic compositions and methods
EP12173008.9A EP2508182B1 (en) 2005-05-12 2006-05-04 Hydralazine for use in the treatment of age-related macular degeneration

Publications (1)

Publication Number Publication Date
PL2508182T3 true PL2508182T3 (pl) 2017-05-31

Family

ID=37431545

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12173008T PL2508182T3 (pl) 2005-05-12 2006-05-04 Hydralazyna do stosowania w leczeniu związanego z wiekiem zwyrodnienia plamki

Country Status (9)

Country Link
US (5) US8088773B2 (enExample)
EP (3) EP2508183B1 (enExample)
JP (2) JP5335419B2 (enExample)
AU (1) AU2006247892B2 (enExample)
CA (1) CA2608163C (enExample)
DE (1) DE202006020318U1 (enExample)
ES (1) ES2598277T3 (enExample)
PL (1) PL2508182T3 (enExample)
WO (1) WO2006124324A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648223A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
US7736860B2 (en) * 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
EP3150215A1 (en) * 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
SG11201408230VA (en) * 2012-06-11 2015-01-29 Macuclear Inc Therapeutic formulation and methods of treatment
CN104955330A (zh) * 2012-09-13 2015-09-30 Cba制药有限公司 粉防己碱药物制剂及方法
US9975910B2 (en) 2013-07-23 2018-05-22 Eisai R&D Management Co., Ltd. Hetero-fused cyclic compound
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
FI3723752T3 (fi) 2017-12-11 2024-11-13 Artelo Biosciences Inc Kannabidiolin uudet kiinteät olomuodot ja niiden käyttötarkoitukset
CN112367971A (zh) * 2018-06-11 2021-02-12 加利福尼亚大学董事会 用以治疗眼睛疾病的脱甲基化
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
EP3949958A1 (en) * 2020-08-04 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound for the treatment and prophylaxis of a lipofuscin-associated disease
CN114276251B (zh) * 2021-12-07 2022-12-16 武汉大学 一种合成硝基(杂)芳烃的方法
US20240285572A1 (en) * 2023-02-27 2024-08-29 Opticgon Llc Compositions comprising nitric oxide-releasing compounds for treating choroidal vascular diseases and methods of their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) * 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
FI873429L (fi) * 1986-08-18 1988-02-19 Houston Biotechnology Oftalmologiska kompositioner foer behandling av nervdegenerationer.
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
IT1201151B (it) 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5194434A (en) * 1991-12-03 1993-03-16 Texas A&M University System Use of OB-101 to treat ocular inflammation
US5252607A (en) 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5422166A (en) * 1993-02-12 1995-06-06 Wangner Systems Corporation Abrasion resisting edge for a forming fabric
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
CN1216469A (zh) 1996-04-26 1999-05-12 藤泽药品工业株式会社 含有二氢吡啶类化合物的眼组织末梢循环改善剂
US6066675A (en) * 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
ES2317650T3 (es) 1996-10-28 2009-04-16 Senju Pharmaceutical Co., Ltd. Farmacos para mejorar trastornos circulatorios oculares.
EP1058546A4 (en) 1998-03-06 2004-07-28 Univ Texas COMPILATIONS AND METHODS FOR THE TREATMENT OF MACULA DISEASES
US6028099A (en) 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
CA2363503C (en) * 1999-03-05 2009-03-10 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
EP1246605A2 (en) * 1999-08-10 2002-10-09 The Board Of Regents, The University Of Texas System Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow
JP4372905B2 (ja) * 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
AU2001259758A1 (en) * 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
AU2003287250B9 (en) * 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
JP2004250347A (ja) * 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20080300292A1 (en) * 2004-11-08 2008-12-04 Nitromed, Inc Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders

Also Published As

Publication number Publication date
US20120196868A1 (en) 2012-08-02
JP5335419B2 (ja) 2013-11-06
EP2508182A1 (en) 2012-10-10
EP2508183A1 (en) 2012-10-10
US8318741B2 (en) 2012-11-27
AU2006247892B2 (en) 2010-04-22
WO2006124324A1 (en) 2006-11-23
US20120115959A1 (en) 2012-05-10
US20060276458A1 (en) 2006-12-07
US20130059841A1 (en) 2013-03-07
US8088773B2 (en) 2012-01-03
EP1885371A4 (en) 2010-04-07
JP2008540528A (ja) 2008-11-20
JP5643263B2 (ja) 2014-12-17
HK1177419A1 (en) 2013-08-23
EP2508182B1 (en) 2016-07-06
US20120071485A1 (en) 2012-03-22
DE202006020318U1 (de) 2008-07-31
AU2006247892A1 (en) 2006-11-23
JP2012229257A (ja) 2012-11-22
EP1885371A1 (en) 2008-02-13
CA2608163C (en) 2011-10-25
CA2608163A1 (en) 2006-11-23
EP2508183B1 (en) 2014-07-09
ES2598277T3 (es) 2017-01-26

Similar Documents

Publication Publication Date Title
ZA200805146B (en) Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
GB2421433B (en) Use of compositions for treating age related macular degeneration or dystrophy
PL2187880T3 (pl) Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej
IL196016A0 (en) Diagnosis and treatment of age related macular degeneration
IL182010A0 (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
IL186408A0 (en) Combination treatment methods
ZA200707639B (en) Methods of decreasing calcification
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
ZA200805148B (en) C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H
PL2252317T3 (pl) Leczenie zwyrodnienia plamki żółtej
PL2508182T3 (pl) Hydralazyna do stosowania w leczeniu związanego z wiekiem zwyrodnienia plamki
EP2132152A4 (en) ARTIFICIAL MARBLE OF VARIOUS MODELS AND METHOD FOR MANUFACTURING THE SAME
ZA200900260B (en) Protection against and treatment of age related macular degeneration
EP2083841A4 (en) TREATMENT OF MACULAR DEGENERATION FROM AGING AND OTHER OCULAR DISEASES
IL190795A0 (en) Genes associated with macular degeneration
EP1937197A4 (en) METHOD AND DEVICE FOR THE TREATMENT OF MACULAR DEGENERATION
IL173971A0 (en) Compositions and methods for treating and preventing age-related macular degeneration
ZA200707420B (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
PL1937252T3 (pl) Kompozycje do stymulowania neurogenezy oraz hamowania degeneracji neuronów
SI1890705T1 (sl) Uporaba 24-nor-UDCA za zdravljenje holestatskih bolezni jeter
GB0523961D0 (en) The treatment of ophthalmic diseases
GB0625844D0 (en) The treatment of macular degeneration
PL1959957T3 (pl) Pochodne pirymidyloaminobenzamidu do leczenia neurowłókniakowatości
GB0511769D0 (en) Treatment
GB0525540D0 (en) New treatment